while semaglutide has been on the market since 2017. There was no word from Novo Nordisk on plans to file the high-dose version for approval, which clearly cuts the efficacy deficit with its main ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Company to host conference call and webcast today at 8:00 a.m. ET--MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc.

Ozempic is hailed as a miracle drug by some people using it to lose weight, however, it isn't suitable for everyone and can ...

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Ozempic, Wegovy and Mounjaro can still be expensive, but pharmacy-produced GLP-1 compounds are becoming much more affordable.

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is in hot pursuit.